Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 8, 2013

Primary Completion Date

September 12, 2019

Study Completion Date

October 24, 2024

Conditions
Endometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaMetastatic Endometrioid AdenocarcinomaRecurrent Malignant Uterine Corpus NeoplasmStage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 StageStage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 StageStage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 StageUterine Corpus Carcinosarcoma
Interventions
DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (19)

15213

UPMC-Magee Womens Hospital, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60637

University of Chicago Comprehensive Cancer Center, Chicago

62526

Decatur Memorial Hospital, Decatur

62702

Southern Illinois University School of Medicine, Springfield

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

T2N 5G2

Arthur J E Child Comprehensive Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital and Cancer Center-General Campus, Ottawa

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01935934 - Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | Biotech Hunter | Biotech Hunter